Nesiritide (Natrecor): recombinant BNP and the ASCEND-HF lesson

Nesiritide (brand name: Natrecor) is a recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid cardiovascular hormone secreted by ventricular cardiomyocytes in response to increased wall stress and volume overload. Produced by Scios (later acquired by Johnson & Johnson), nesiritide received FDA approval in 2001 for the intravenous treatment of acute decompensated heart failure in patients with dyspnea at rest or with minimal activity. The drug was initially adopted with enthusiasm as a physiologically elegant approach to heart failure — supplementing an endogenous cardiac hormone to achieve vasodilation and natriuresis. However, its subsequent clinical trajectory was marked by safety controversies and, ultimately, by the ASCEND-HF trial published in the New England Journal of Medicine in 2011, which demonstrated that nesiritide provided no mortality benefit and no reduction in heart failure readmissions. This honest account examines the science, the trials, and nesiritide's current marginal clinical role.

What is nesiritide?

Nesiritide is a 32-amino acid recombinant human BNP produced in E. coli using recombinant DNA technology. The sequence is identical to endogenous human BNP-32, the mature cleavage product of proBNP secreted by ventricular myocardium in response to wall stress, pressure overload, and volume overload. Endogenous BNP serves as a counter-regulatory hormone in heart failure, opposing the sodium-retaining and vasoconstrictive effects of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system. The molecular weight of nesiritide is approximately 3,464 Da. It is supplied as a lyophilized powder for intravenous infusion and is administered only in monitored hospital settings due to the risk of hypotension.

Nesiritide acts on natriuretic peptide receptor A (NPR-A, also called GC-A), a membrane guanylate cyclase coupled receptor that raises intracellular cyclic GMP (cGMP) upon activation. This leads to vascular smooth muscle relaxation (vasodilation), renal tubular natriuresis, and inhibition of RAAS and sympathetic outflow. The net hemodynamic effect is reduction in pulmonary capillary wedge pressure (PCWP), systemic vascular resistance, and right atrial pressure, accompanied by modest increases in cardiac output — without direct positive inotropic effects. These effects made it appealing as an acute decompensated heart failure therapy.

Mechanism of action

Nesiritide binds NPR-A on vascular smooth muscle, endothelial cells, renal tubular cells, and cardiomyocytes. NPR-A activation converts GTP to cGMP, activating protein kinase G (PKG), which phosphorylates myosin light chain kinase and other targets to promote smooth muscle relaxation. In the kidney, cGMP signaling in the collecting duct inhibits sodium reabsorption and promotes natriuresis — the excretion of sodium and water. In the systemic vasculature, arteriolar and venular dilation reduces both preload and afterload on the failing ventricle. The drug also suppresses renin, aldosterone, and endothelin-1 secretion. The pharmacological profile is therefore a combination of venodilation, arteriodilation, natriuresis, and neurohormonal suppression.

What the research shows

The 2000 NEJM paper by Colucci et al. (PMID 10901239) demonstrated that nesiritide infusion significantly reduced PCWP and improved dyspnea compared to placebo and to standard IV nitroglycerin in patients with acute decompensated heart failure. This hemodynamic and symptomatic benefit formed the basis of FDA approval in 2001. Initial enthusiasm was strong: nesiritide use grew rapidly as physicians sought alternatives to dopamine and dobutamine, which carry proarrhythmic and ischemic risks.

The enthusiasm began to erode after 2005 when a meta-analysis by Sackner-Bernstein et al. raised concerns about increased 30-day mortality with nesiritide and substantial worsening of renal function. These analyses were contested methodologically, but they triggered a significant decline in use and prompted the design of a large definitive trial. The ASCEND-HF trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) was the response: a randomized, double-blind, placebo-controlled trial at 398 centers worldwide enrolling 7,141 patients with acute decompensated heart failure. Results were published by O'Connor et al. in the New England Journal of Medicine on January 27, 2011 (PMID 21080835).

ASCEND-HF found that nesiritide produced modest and statistically marginal improvement in dyspnea at 6 hours (44.5% vs. 42.1%, P=0.03) and 24 hours (68.2% vs. 66.1%, P=0.007), but these did not meet the prespecified level of significance. On the hard endpoint — rehospitalization for heart failure or death from any cause within 30 days — nesiritide was not superior to placebo (9.4% vs. 10.1%; P=0.31). There was no mortality benefit at 30 days (3.6% vs. 4.0%; P not significant). Nesiritide did not worsen renal function on average but was significantly associated with hypotension (26.6% vs. 15.3%). The trial authors explicitly stated they could not recommend nesiritide for the majority of acute heart failure patients. Use of nesiritide has declined sharply since the ASCEND-HF results were published. It is not recommended in current major heart failure guidelines (AHA/ACC, ESC) as routine therapy for acute decompensated heart failure.

Pharmacokinetics

Nesiritide is administered intravenously only — as a bolus followed by a continuous infusion — in a hospital setting. The mean terminal half-life is approximately 18 minutes (range 10–20 minutes). Distribution occurs primarily in the central compartment (plasma and extracellular fluid) and the drug is cleared by three parallel mechanisms: (1) binding to and internalization through NPR-C (the clearance receptor); (2) proteolytic cleavage by neutral endopeptidase (neprilysin, the same enzyme targeted by sacubitril in sacubitril/valsartan); and (3) renal filtration. The very short half-life means hemodynamic effects dissipate within 30–60 minutes of stopping the infusion — a favorable property for managing hypotension, which was the drug's most clinically significant adverse effect.

Approved indication and dose range

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Natrecor (nesiritide) is FDA-approved for improvement of dyspnea in patients with acute decompensated heart failure who have dyspnea at rest or with minimal activity. The approved dosing from labeling is an IV bolus of 2 mcg/kg followed by a continuous infusion of 0.01 mcg/kg/min. The infusion may be titrated upward by 0.005 mcg/kg/min, no more frequently than every 3 hours, to a maximum of 0.03 mcg/kg/min. Blood pressure must be monitored closely due to hypotension risk. Nesiritide is not approved for and should not be used as a replacement for diuretics; its role is hemodynamic augmentation as an adjunct to standard heart failure therapy. Given the ASCEND-HF results, many centers reserve it for refractory cases.

Storage and handling

Natrecor is supplied as a lyophilized powder (1.5 mg per vial) for reconstitution and intravenous infusion. Vials should be stored at 2–25 °C; they may be stored at up to 25 °C for up to 24 hours after reconstitution. Reconstituted and diluted solution should be stored at 2–25 °C and administered within 24 hours. Nesiritide is for hospital/clinical use only and is not available as a research peptide for self-administration purposes. The product should not be frozen after reconstitution.

What nesiritide is NOT

Nesiritide is not a survival drug for heart failure. ASCEND-HF established that it does not reduce mortality or heart failure readmissions. It is not a diuretic and should not be used as a substitute for loop diuretics in volume-overloaded patients. It is not related to natriuretic peptide biomarkers used for heart failure diagnosis (the BNP blood test): while nesiritide is a recombinant form of BNP, administering it will elevate measured BNP levels and confound biomarker interpretation. Nesiritide should not be confused with sacubitril/valsartan (Entresto), which works by inhibiting the enzyme that degrades endogenous natriuretic peptides (neprilysin) and has strong mortality benefit data in chronic heart failure with reduced ejection fraction. Nesiritide is not available outside hospital infusion settings and is not in the research peptide market.

References

Key sources include the pivotal approval trial (Colucci et al., NEJM 2000; PMID 10901239), the ASCEND-HF trial (O'Connor et al., NEJM 2011; PMID 21080835), the ASCEND-HF renal subanalysis (PMC4196257), the Natrecor DailyMed prescribing information, and the NERDCAT ASCEND-HF study summary.